Evaluation of earlier versus later dietary management in long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein deficiency: a systematic review.
Inborn errors of metabolism
Long-chain 3-hydroxyacyl-CoA dehydrogenase
Long-term outcomes
Mitochondrial trifunctional protein deficiency
Newborn screening
Systematic review
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
08
07
2019
accepted:
09
10
2019
entrez:
16
11
2019
pubmed:
16
11
2019
medline:
25
7
2020
Statut:
epublish
Résumé
Mitochondrial trifunctional protein (MTP) and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiencies are rare fatty acid β-oxidation disorders. Without dietary management the conditions are life-threatening. We conducted a systematic review to investigate whether pre-symptomatic dietary management following newborn screening provides better outcomes than treatment following symptomatic detection. We searched Web of Science, Medline, Pre-Medline, Embase and the Cochrane Library up to 23rd April 2018. Two reviewers independently screened titles, abstracts and full texts for eligibility and quality appraised the studies. Data extraction was performed by one reviewer and checked by another. We included 13 articles out of 7483 unique records. The 13 articles reported on 11 patient groups, including 174 people with LCHAD deficiency, 18 people with MTP deficiency and 12 people with undifferentiated LCHAD/MTP deficiency. Study quality was moderate to weak in all studies. Included studies suggested fewer heart and liver problems in screen-detected patients, but inconsistent results for mortality. Follow up analyses compared long-term outcomes of (1) pre-symptomatically versus symptomatically treated patients, (2) screened versus unscreened patients, and (3) asymptomatic screen-detected, symptomatic screen-detected, and clinically diagnosed patients in each study. For follow up analyses 1 and 2, we found few statistically significant differences in the long-term outcomes. For follow up analysis 3 we found a significant difference for only one comparison, in the incidence of cardiomyopathy between the three groups. There is some evidence that dietary management following screen-detection might be associated with a lower incidence of some LCHAD and MTP deficiency-related complications. However, the evidence base is limited by small study sizes, quality issues and risk of confounding. An internationally collaborative research effort is needed to fully examine the risks and the benefits to pre-emptive dietary management with particular attention paid to disease severity and treatment group.
Sections du résumé
BACKGROUND
Mitochondrial trifunctional protein (MTP) and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiencies are rare fatty acid β-oxidation disorders. Without dietary management the conditions are life-threatening. We conducted a systematic review to investigate whether pre-symptomatic dietary management following newborn screening provides better outcomes than treatment following symptomatic detection.
METHODS
We searched Web of Science, Medline, Pre-Medline, Embase and the Cochrane Library up to 23rd April 2018. Two reviewers independently screened titles, abstracts and full texts for eligibility and quality appraised the studies. Data extraction was performed by one reviewer and checked by another.
RESULTS
We included 13 articles out of 7483 unique records. The 13 articles reported on 11 patient groups, including 174 people with LCHAD deficiency, 18 people with MTP deficiency and 12 people with undifferentiated LCHAD/MTP deficiency. Study quality was moderate to weak in all studies. Included studies suggested fewer heart and liver problems in screen-detected patients, but inconsistent results for mortality. Follow up analyses compared long-term outcomes of (1) pre-symptomatically versus symptomatically treated patients, (2) screened versus unscreened patients, and (3) asymptomatic screen-detected, symptomatic screen-detected, and clinically diagnosed patients in each study. For follow up analyses 1 and 2, we found few statistically significant differences in the long-term outcomes. For follow up analysis 3 we found a significant difference for only one comparison, in the incidence of cardiomyopathy between the three groups.
CONCLUSIONS
There is some evidence that dietary management following screen-detection might be associated with a lower incidence of some LCHAD and MTP deficiency-related complications. However, the evidence base is limited by small study sizes, quality issues and risk of confounding. An internationally collaborative research effort is needed to fully examine the risks and the benefits to pre-emptive dietary management with particular attention paid to disease severity and treatment group.
Identifiants
pubmed: 31730477
doi: 10.1186/s13023-019-1226-y
pii: 10.1186/s13023-019-1226-y
pmc: PMC6858661
doi:
Substances chimiques
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase
EC 1.1.1.211
Mitochondrial Trifunctional Protein
EC 2.3.1.16
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
258Subventions
Organisme : Department of Health
ID : CDF-2016-09-018
Pays : United Kingdom
Références
J Inherit Metab Dis. 2017 Nov;40(6):831-843
pubmed: 28871440
Acta Ophthalmol. 2008 May;86(3):329-37
pubmed: 18162058
J Inherit Metab Dis. 2009 Aug;32(4):488-97
pubmed: 19399638
Clin Chem. 2001 Nov;47(11):1945-55
pubmed: 11673361
J Inherit Metab Dis. 2014 Nov;37(6):889-98
pubmed: 25022222
Mol Genet Metab. 2012 Nov;107(3):281-93
pubmed: 22795865
JIMD Rep. 2013;8:81-90
pubmed: 23430524
J Inherit Metab Dis. 1990;13(3):311-4
pubmed: 2122092
Mol Genet Metab. 2011 Aug;103(4):341-8
pubmed: 21549624
Orphanet J Rare Dis. 2011 Jun 20;6:44
pubmed: 21689452
J Pediatr. 2003 Jun;142(6):684-9
pubmed: 12838198
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
Ophthalmology. 2016 Oct;123(10):2183-95
pubmed: 27491397
Pediatrics. 2002 Jan;109(1):99-104
pubmed: 11773547
J Hum Genet. 2017 Sep;62(9):809-814
pubmed: 28515471
BMC Pediatr. 2018 Mar 8;18(1):103
pubmed: 29519241
J Inherit Metab Dis. 2006 Feb;29(1):76-85
pubmed: 16601872
Acta Paediatr. 2016 May;105(5):549-54
pubmed: 26676313
J Inherit Metab Dis. 2010 Oct;33(5):555-61
pubmed: 20830526
Orphanet J Rare Dis. 2015 Feb 22;10:21
pubmed: 25888220
Mol Genet Metab. 2010 Oct-Nov;101(2-3):205-7
pubmed: 20659813
Acta Paediatr. 2016 Dec;105(12):1451-1460
pubmed: 27461099
Worldviews Evid Based Nurs. 2004;1(3):176-84
pubmed: 17163895
JIMD Rep. 2017;31:63-71
pubmed: 27117294
J Inherit Metab Dis. 2011 Feb;34(1):185-95
pubmed: 21103935
Am J Obstet Gynecol. 2002 Sep;187(3):715-20
pubmed: 12237653
Mol Genet Metab. 2005 Jun;85(2):108-14
pubmed: 15896654